Showing 126–150 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Eva Sodja, Nataša Toplak, Simon Koren, M. Kovač, Sara Truden, et al.
Drug resistant tuberculosis (TB), especially multidrug (MDR) and extensively drug-resistant (XDR) TB, is still a serious problem in global TB control. Slovenia and North Macedonia are low-incidence countries with TB incidence rates of 5.4 and 10.4 in 2017, respectively. In both c…
Naveen Pandhi, Ritu Dadra, Balbir Malhotra, Dr. P Prasanth
…ases were in the age group of 21-30 years, 147 (73.5%) were drug susceptible (DS) and 53 (26.5%) were drug resistant (DR). Amongst DR-TB cases, 21 (18.7%) were new and 32 (36.4%) were previously treated cases. Rifampicin mono-resistance was higher in both new (47.6%) and previous…
Tamilarasu Kadhiravan
Drug-resistant tuberculosis is an important public health problem. 1 Erratic adherence to antituberculosis treatment often results in treatment failure and is widely considered to be the driving force behind the emergence of drug-resistance in previously treated patients."Drugs d…
Chansuda Wongsrichanalai, Michael E. Kimerling, Jay K. Varma, John R. MacArthur, Jonathan J. Juliano
Drug resistance in malaria and in tuberculosis (TB) are major global health problems. Although the terms multidrug-resistant TB and extensively drug-resistant TB are precisely defined, the term multidrug resistance is often loosely used when discussing malaria. Recent declines in…
Pooja Sadana, Vishal Verma, Priyanka Devgun
…g the global TB control. The success rate of treating multi drug resistant remains very low. Method: This cross-sectional study was conducted on all MDR-TB patients who were registered and being treated under PMDT services in Amritsar district from 1st January 2015 to 31st Decemb…
Malik Olatunde Oduoye, Hiba Zafar, Umer Wamiq, Suheera Afzoon, Hafsa Shuja, et al.
…c health concern, particularly due to the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. The severity of cough in TB is a critical symptom with the potential for transmission and clinical monitoring. However, the association between gene…
R Santosh
Introduction: Drug-resistant tuberculosis is a major public health problem throughout world. India accounts for 27% of global TB burden. More than half of TB patients in India are cared for in private sector. Usage of inappropriate TB diagnostic, treatment practices and lack of a…
Apoorva Narain, Surya Kant, Rikesh K. Dubey, Kanchan Srivastava, Anand Kumar Maurya
…onential increase in tuberculosis (TB) cases, mainly by the drug-resistant (DR) strains of MTB, has created an urgent need for identifying and developing new antituberculosis drugs acting via novel mechanisms. The multi drug-resistant (MDR) TB and extensively drug-resistant (XDR)…
Diksha Zine, Nilma Hirani, Ameeta Joshi
Introduction: Drug-resistant tuberculosis is a major global health issue. Multidrug-resistant TB (MDRTB) and extensively drug-resistant TB (XDR-TB) are particularly concerning. Conventional phenotypic methods being cumbersome and time consuming, molecular assays for the detection…
Н. А. Мацегора, S.O. Polyakova
…logical and biochemical disorders in patients with isolated drugs resistant tuberculosis (DRTB) and coinfection of DRTB/HIV/AIDS in the terminal phase, to assess the extent of their linear relationship.Materials and methods. The method of continuous sampling analyzed the histori…
Brigitta Derendinger, Anzaan Dippenaar, Margaretha de Vos, S. Huo, Rencia Alberts, et al.
…ion Bedaquiline (BDQ) is a lifesaving new tuberculosis (TB) drug undergoing global scale-up. Data on resistance emergence in programmatic settings, especially in patients resistant to other drugs with potentially weak background regimens, is scarce. Such individuals are a priorit…
L.D. Todoriko, V.I. Petrenko, О.С. Шевченко, S.B. Noreіko, Ihor Semianiv, et al.
…t research on molecular genetic aspects of the formation of resistance in tuberculosis patients to avoid it during use of modern treatment programs. Objective — to assess the situation with the evolution of resistance of Mycobacteria tuberculosis and the stages of drug resistance…
Baijayantimala Mishra, PrasantaRaghab Mohapatra
Multidrug-resistant tuberculosis (MDR-TB) is one of the most pressing and problematic challenges being faced globally. The dynamic transmission microsimulation model of TB in India estimates that 42 per cent of the new MDR cases are spread by transmission and this proportion cont…
Deepshikha Singh, Vikram Jeet Singh, Subhankar P. Mandal, Karen N. DSouza, B. R. Prashantha Kumar, et al.
Abstract: Multi drug-resistant or extensive drug resistance Mycobacterium tuberculosis poses numerous challenges for health care workers and for public health authorities. Treating multidrug resistant or extensive drug resistance tuberculosis continues to be a difficult task, as …
G.I.A. Okoroiwu, Gloria I. Onokpise
Introduction: The occurrence of multi-drug resistance tuberculosis among tuberculosis patients has raised global public health concern, especially in Nigeria. The increase in the number of cases of resistance tuberculosis despite the effort and need to curb the menace in Nigeria …
Anupa Thampy, Marilyn Mary Ninan, Joy Sarojini Michael, Priscilla Rupali
Abstract Background Treatment of drug-resistant tuberculosis (DR-TB) requires toxic and complex drug regimens. Dismal outcomes occur due to a delay in the report of susceptibility results. WHO endorses genotypic tests like line probe assay (Mtbdrsl) for an early diagnosis enablin…
Halisyah Hasyim Lubis
Introduction: Drug-resistant tuberculosis (DR TB) is a condition where Mycobacterium tuberculosis is resistant to isoniazid, rifampicin or resistant to isoniazid and rifampin as well as other first-line anti-tuberculosis drugs (OAT). Tuberculosis (TB) is a contagious infectious d…
Atit Puspitasari Dewi
<b>Background:</b> Drug-resistant tuberculosis (DR-TB) remains a high burden disease in Indonesia with approximately 9038 (1.6%) laboratory-confirmed DR-TB cases found in 2018. Decentralization strategy for DR-TB treatment in primary care apllied in rural area. <b>Objectives:</b>…
Naoufal Sirri, Christophe Guyeux, Christophe Sola
…is a major public health problem, and the diagnosis of multidrug-resistant and extensively drug-resistant <italic>tuberculosis</italic> is a global health priority. This resistance is mainly caused by mutations in genes coding for drug targets or conversion enzymes, but knowledge…
Mandlenkosi Manika, Lindiwe Modest Faye, Ntandazo Dlatu, Mojisola Clara Hosu
Background: The global burden of drug-resistant Mycobacterium tuberculosis continues to threaten tuberculosis control efforts, largely due to the emergence and transmission of resistance-associated genetic mutations. Molecular epidemiology provides critical insights into mutation…
Chirag J Gohil, Ketan C. Parmar, Priyanka R. Patel, Jignakumari J. Gohil
Drug resistance in tuberculosis has been shown to result from spontaneous mutation in several chromosomal genes of M.Tuberculosis. Mutation may reduce the medications' capacity to bind to the target genes. In many patients polydrug resistance, multidrug resistance, rifampicin res…
Jin Mo Goo, M.D.
…renchyma in close contacts at high risk for developing multidrug- or extensively drug-resistant Tb by using a follow-up ultralow dose CT scan. Multidrug- or extensively resistant tuberculosis tuberculosis is a major public health threat worldwide and the global burden of drug-re…
Salam El Achkar
…, with 10 million new cases estimated worldwide in 2017. TB drug resistance and its diagnosis are particularly problematic. Only 25% of the 450,000 incident multidrug resistant (MDR) TB patients estimated over the same year were diagnosed and treated as such.Although Lebanon is a…
Muhammad Arslan, Rohan Arshad, Faizan Hameed, Sidra Iqbal, Ijaz Ahmad, et al.
Background: The rise of drug-resistant tuberculosis (TB) poses a critical challenge to global TB control efforts, with multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains complicating treatment outcomes. The fitness cost associated with drug resistance mutat…
Suman Saurabh, Pankaj Bhardwaj
The WHO consolidated guidelines covering the treatment of drug-resistant tuberculosis has been released on June 15, 2020.[1] Its release was much anticipated since it was announced in a rapid communication issued in December 2019. The 2020 guidelines[1] are in continuation to the…